Why the Immutep (ASX:IMM) share price is up 6% today

The Immutep Ltd (ASX: IMM) share price is soaring in early-afternoon trade following a collaboration agreement. Here's the latest.

| More on:
Five stacked building blocks with green arrows, indicating rising inflation or share prices

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Immutep Ltd (ASX: IMM) share price is soaring in early-afternoon trade. This comes after the company announced a second clinical trial collaboration with subsidiaries of Merck & Co. (MSD). At the time of writing, the biotechnology company's shares are up 5.97% to 36 cents.

New Phase 2b trial

The Immutep share price is on the move as investors have been rallying up on the positive news.

According to its release, Immutep advised that it has entered a second clinical trial collaboration and supply agreement with MSD. This will see Immutep commence a new Phase 2b trial, named TACTI-003 using first-line head and neck squamous cell carcinoma (HNSCC) patients.

HNSCC is an aggressive life-threatening cancer that affects either the mouth, sinuses, nose or throat. The disease has a high mortality rate. Because of this, it is considered one of the most common cancers in the world. Global cancer statistics revealed 890,000 cases were diagnosed with 450,000 deaths reported in 2018 alone.

The trial will be a 1:1 randomised and controlled study involving around 160 first-line HNSCC patients. Furthermore, Immutep will seek to assess the safety and efficacy of its lead product candidate, eftilagimod alpha with MSD's KEYTRUDA (pembrolizumab). This will be compared against administering pembrolizumab alone to treat the HNSCC disease.

Immutep's TACTI-003 trial will take place over multiple locations across the United States, Australia, and Europe. Moreover, the first patient is expected to be enrolled in the study during the middle of this year.

It's worth noting that the company is also evaluating eftilagimod alpha and KEYTRUDA in its Phase 2 TACTI-002 trial. The encouraging results received led Immutep to conduct an additional TACTI-003 study.

Words from the CEO

Furthermore, Immutep CEO Marc Voigt touched on the company's developments, saying:

We are excited to be deepening our collaboration with MSD through this second agreement and the TACTI-003 clinical trial. Advancing to this later stage Phase IIb trial will allow us to explore the combination therapy in the commercially relevant 1st line therapy setting which has a high unmet medical need.

About the Immutep share price

The Immutep share price has gained close to 30% over the past 12 months. However, the company is down 13% year-to-date.

Based on the current valuations, Immutep has a market capitalisation of about $233.5 million. Additionally, Immutep has 648 million shares on issue.

Should you invest $1,000 in Medlab Clinical right now?

Before you buy Medlab Clinical shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Medlab Clinical wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A woman's hand draws a stylised 'Top Ten' on a projected surface.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another tough day for investors this Tuesday.

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why HMC Capital, Platinum, Sigma, and Skycity shares are dropping today

These shares are having a tough session on Tuesday. But why?

Read more »

A close-up photo of a ballot box with an Australian flag in front of it and a gentleman's hands placing his vote in the 2022 election inside the box
Share Market News

How these ASX 200 stocks are primed to gain from Labor's resounding Federal election win

With the Federal election in the rear-view, which ASX 200 stocks should I buy now?

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Share Gainers

Why Dimerix, Evolution Mining, Inghams, and NextDC shares are charging higher today

These shares are rising when many are falling today. But why?

Read more »

Smiling young woman eating chocolate outdoors.
Share Market News

The See's Candies playbook for ASX investors

Two ASX businesses that remind me of Buffett’s sweetest investment.

Read more »

Man smiling at a laptop because of a rising share price.
Opinions

My 2 favourite ASX sectors to invest in

Finding your groove can help your investing success.

Read more »

Legendary share market investing expert and owner of Berkshire Hathaway Warren Buffett
Opinions

3 things I learned from Warren Buffett being the CEO of Berkshire Hathaway

The Oracle from Omaha is in his last year as CEO.

Read more »

A male ASX 200 broker wearing a blue shirt and black tie holds one hand to his chin with the other arm crossed across his body as he watches stock prices on a digital screen while deep in thought
Share Market News

5 things to watch on the ASX 200 on Tuesday

Here's what to expect on the local market today.

Read more »